AstraZeneca Plans a Blockbuster Product for 2023 Amid Falling Demand for Covid Vaccines

As a result of the unusually aggressive market, activists have seen opportunities to invest in sectors and individual companies in which they have never had access to funds before.

‍

According to Ms. Deignan, activism in the United States increased by 40% last year.

‍

An activist will look for an undervalued company with good assets, and is willing to push for a board seat if the opportunity arises, she said. For finance chiefs to avoid being targeted by activists, they need to understand what shareholders care about, such as good capital allocation strategies and management access, according to Ms. Deignan. 

‍

Then you'll be fine," she remarked jokingly.  

‍

As Covid-19 enters its fourth year of outbreak, the need for vaccines to combat the disease has dropped. However, AstraZeneca is working on new projects that it expects will generate billions of dollars in revenue over the next several years.

According to Trade Algo, it is expected that 30 phases and three clinical trials will start this year, of which more than ten products should be selected as blockbuster products or products that will achieve a revenue target of more than $1 billion, or something like that.

According to her, "Really, it's not just the top line revenue growth, but also the reinvestment in the business that continues to drive innovation, which is driving long term growth, that continues to drive growth in the business," she added.

‍

According to the company's fourth-quarter results on Thursday, the British-Swedish pharmaceutical firm is forecasting growth in earnings and revenue for 2023, as its roots in the pharmaceutical sector helped it to post a net profit of $901 million for the quarter.

‍

As a result of these growths, AstraZeneca grew its oncology, cardiovascular, renal, metabolism, and rare diseases businesses by around 20%, respiratory, immunology, and vaccines businesses by 3%, and rare diseases grew by around 10%.

Sarin informed Trade Algo that the growth is a cross-sectional phenomenon, in which we are seeing strong growth in all geographies.

‍

Drugs In The Pipeline

Pascal Soriot, CEO of AstraZeneca, spoke at a media conference on Thursday to provide details on a number of the drugs that are currently going through phase three trials.

There is some evidence to suggest that Camizestrant reduces the risk of progression of breast cancer, as well as death as a result of certain types of breast cancer by over 42% when patients are taking a 75mg dose of the drug. The comparison here is between Faslodex, a drug commonly used in the industry for the purpose of selective estrogen receptor degraders or SERDs.

This deal will result in AstraZeneca acquiring CinCor Pharma, including the rights to barostat, a cardiorenal drug that will be tested for its efficacy in the treatment of resistant hypertension and chronic kidney disease through clinical trial management.

Asfotase alpha, the last of the drugs Soriot recommended as having "promising data" is a drug that could improve the standard of care for patients with hypophosphatasia, a rare genetic condition affecting the bones and teeth that causes calcium deposits to form on them.

According to Soriot, AstraZeneca will continue to deliver the fastest revenue growth in the industry in the years ahead. It is on a course to deliver at least 15 new medicines by the end of the decade, setting itself up to lead the industry.

There was a slight rise in AstraZeneca's stock price as early as 10 a.m. on Thursday morning, which then dropped back slightly by midday to 4.7%, before increasing somewhat by midday again to 4.8%.